Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Jonathan Robert Hunt is Chief Financial Officer at Perspective Therapeutics. OQRO lists 4 transactions filed with the SEC under this name, the latest on Nov 27, 2024, each linked to the official Form 4.
Chief Financial Officer
Disclosures on record
4
Companies involved
1
As of the latest filing on , Jonathan Robert Hunt reported holding 48,800 shares of Perspective Therapeutics (CATX), worth about $46K at the last close of $1 (Nov 13, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Perspective Therapeutics CATX | 48,800 | 49K direct | $1 | $46K | Nov 25, 2024 |
Is this Jonathan Robert Hunt’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
1 buy, median −37.1 pts vs S&P 500, beat it 0 of 1 time.
Average −37.1 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Nov 27, 2024 to Nov 27, 2024, measured from the first close after the filing. Past results, not a forecast.
1 purchase disclosed; 0% of the 1 measured at 90 days finished ahead of the index.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 82 ranked insiders is −5.5 pts (median, against the S&P 500).
Equal weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
Perspective TherapeuticsCATX
4 disclosures · Nov 2024 · 4 bought
Nov 25, 2024Bought~$39Kdisclosed Nov 27
DetailsOfficial recordNov 25, 2024Bought~$8.6Kdisclosed Nov 27
DetailsOfficial recordNov 25, 2024Bought~$1.4Kdisclosed Nov 27
DetailsOfficial recordNov 25, 2024Bought~$114disclosed Nov 27
DetailsOfficial recordJonathan Robert Hunt bought shares on the open market in 2020, 2022, 2023 and 2024, and has not bought since 2024.
Jonathan Robert Hunt reported 13 open-market purchases and 0 sales since 2020; purchases in 4 different years, most recently 2024.
| Year | Bought | Sold |
|---|---|---|
| 2024 | $102K7×7 trades | — |
| 2023 | $33K1×1 trade | — |
| 2022 | $44K4×4 trades | — |
| 2020 | $35K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Jonathan Robert Hunt reported 13 open-market purchases and 0 sales here, 2020 to 2024.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
On the latest SEC Form 4, dated Nov 25, 2024, Jonathan Robert Hunt reported holding 48,800 shares of Perspective Therapeutics (CATX). At the last close of $1 on Nov 13, 2026, that is about $46K. This is the stake disclosed in filings, not a net worth.
Jonathan Robert Hunt bought shares on the open market in 2020, 2022, 2023 and 2024, and has not bought since 2024.
In SEC filings since 2020: the latest open-market purchase is from 2024; no open-market sale is on record.
Perspective Therapeutics (CATX), from 2020 to 2024: 13 purchases and 0 sales.
